ArticleInternational clinical psychopharmacology2015
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Article in International clinical psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.BMC psychiatry · 2020Trial
- Lurasidone vs. Other Antipsychotics as Augmentation Strategies for Clozapine in Treatment-resistant Schizophrenia: An Observational Multicenter Prospective Study.Current neuropharmacology · 2026Observational
- Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo-controlled trials.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.Frontiers in psychiatry · 2024Article
- Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance.World journal of psychiatry · 2023Article
- Lurasidone for the treatment of schizophrenia in adult and paediatric populations.Drugs in context · 2023Review
- Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression.Consortium psychiatricum · 2022Article
- Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.Neurology and therapy · 2021Article
- Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain.Neuropsychiatric disease and treatment · 2021Article
- Identification of clinical phenotypes in schizophrenia: the role of lurasidone.Therapeutic advances in psychopharmacology · 2021Review
- Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia.International journal of general medicine · 2021Article
- Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda.BioMed research international · 2019Article
- Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment.International journal of bipolar disorders · 2017Article
- Physical Health and Drug Safety in Individuals with Schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Review
- Rapid-onset clozapine-induced loss of glycaemic control: case report.BJPsych open · 2017Article
- Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.Annals of general psychiatry · 2017Article
- Schizophrenia relapse, patient considerations, and potential role of lurasidone.Patient preference and adherence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this analysis was to evaluate the effect of 12 months of treatment with lurasidone on weight in patients with schizophrenia. Post-hoc, observed-case analysis included pooled data from six studies on 40-160 mg/day lurasidone; two studies included active comparators (2-6 mg/day risperidone or 200-800 mg/day quetiapine XR). Overall, 593 patients completed 12 months of treatment (N=471 lurasidone, N = 89 risperidone, N = 33 quetiapine XR). The mean baseline weight was 72.8, 80.8, and 72.4 kg in the lurasidone, risperidone, and quetiapine XR groups, respectively. The mean weight change at month 12 was -0.4 kg with lurasidone, +2.6 kg with risperidone, and +1.2 kg with quetiapine XR. Weight gain of at least 7% from study baseline was observed in 16.0, 25.8, and 15.2% of patients, and weight loss of at least 7% was seen in 18.5, 6.7, and 9.1% of patients treated with lurasidone, risperidone, and quetiapine XR, respectively. A shift from normal/underweight baseline BMI status to overweight/obese at month 12 occurred in 10.2, 27.6, and 15.0% of patients in the lurasidone, risperidone, and quetiapine XR groups, respectively. Conversely, 14.3, 1.7, and 7.7% of patients, respectively, shifted from overweight/obese to normal/underweight. In summary, a low potential for clinically significant weight gain was observed in patients with schizophrenia treated continuously with lurasidone for 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.